Summary: Cynomolgus CYP2C76, not orthologous to any human cytochrome P450, partly accounts for species differences in drug metabolism between cynomolgus macaques and humans. To discover the CYP2C76 variants, we previously surveyed cynomolgus macaque genomes and found several nonsynonymous variants, including a null allele. However, the analysis was limited to cynomolgus macaques, and the number of genomes was relatively small. In this study, therefore, further screening was conducted using 74 cynomolgus and 30 rhesus macaques. A total of 18 non-synonymous variants was found, among which 7 were in substrate recognition sites, important for protein function, and 14 (74%) were shared by both macaque lineages. In cynomolgus macaques, 3 (16%) non-synonymous variants were unique to Indochinese animals, whereas all the variants found in Indonesian animals were shared by Indochinese animals. Among the 18 variants, as compared with the wild type, in progesterone 16¡-hydroxylation, L65F, M310L, and N364S variants showed lower metabolic activity and lower intrinsic clearance by kinetic analysis. Molecular modeling indicated that the reduced catalytic activity of the L65F variant in progesterone 16¡-hydroxylation possibly resulted from a longer distance of progesterone to the heme in the active site of the CYP2C76 protein. L65F, M310L, and N364S variants might partly influence inter-animal variations of CYP2C76 metabolic activities.
Introduction
In humans, the CYP2C subfamily, including CYP2C8, CYP2C9, and CYP2C19, is important for the metabolism of approximately 20% of the prescribed drugs such as paclitaxel, tolbutamide, and omeprazole, 1¥ as well as endogenous substrates such as progesterone. 2¥ Numerous variants have been found in human CYP2C genes ¤see http://www. imm.ki.se/CYPalleles/¥, some of which are responsible for inter-individual variation in drug metabolism. For example, a poor metabolizer of phenytoin, glipizide, and tolbutamide has been found to be homozygous for CYP2C9*3, which is present in Caucasians at a frequency of approximately 6%, and the reduced metabolic activity mostly is accounted for by higher K m and lower V max ¤lower intrinsic clearance¥. 1¥ Therefore, human CYP2C variants are important in drug metabolism studies.
Macaques, including cynomolgus macaques ¤Macaca fascicularis¥ and rhesus macaques ¤Macaca mulatta¥, are widely used in drug metabolism studies. In the cynomolgus CYP2C subfamily, CYP2C20, CYP2C43, CYP2C75, and CYP2C76 show relatively abundant expression in the liver and metabolize human CYP2C substrates. 3¥ Among these CYP2C mRNAs, CYP2C76 mRNA was most abundantly expressed in cynomolgus macaque liver, 3¥ making CYP2C76 a major CYP2C in the liver. Moreover, CYP2C76 is not orthologous to any human cytochrome P450 ¤P450¥, 4¥ and accounts for species differences in pitavastatin metabolism between cynomolgus macaques and humans. 5¥ Therefore, CYP2C76 could be an important enzyme to be considered in drug metabolism studies using cynomolgus macaques.
We previously surveyed cynomolgus macaque genomes and found several non-synonymous variants, including a null allele ¤c.449TGhA¥ in CYP2C76, which causes a frameshift and premature termination codon in an exon 3. 6¥ However, the genomes analyzed were limited to cynomolgus macaques, and the number of genomes was relatively small. In this study, therefore, we extended our attempts using 74 cynomolgus and 30 rhesus macaques. For all nonsynonymous variants identified, their effects for CYP2C76 protein function were investigated by metabolic assays of variant proteins using progesterone as the substrate.
Materials and Methods

Chemicals and reagents:
Oligonucleotides were synthesized by Invitrogen ¤Tokyo, Japan¥. All the chemicals used were of the analytical grade from commercial sources such as Sigma-Aldrich ¤St. Louis, MO¥.
Animals and genomic DNA extraction: Whole blood samples were collected from 74 cynomolgus macaques ¤40 from Indochina and 34 from Indonesia, 4®5 years of age, 3®5 kg¥ and 30 rhesus macaques ¤from China, 7 years of age, weighing 3®5 kg¥. Genomic DNA was prepared from these blood samples using the Gentra Puregene Blood kit ¤Qiagen, Valencia, CA¥ according to the manufacturerös instructions. This study was reviewed and approved by the Institutional Animal Care and Use Committee of Shin Nippon Biomedical Laboratories, Ltd. ¤Kainan, Japan¥.
Re-sequencing and variant identification: To identify the CYP2C76 variants, direct sequencing was performed as described previously. 6¥ Briefly, polymerase chain reaction ¤PCR¥ was performed in 20-µl reactions containing 1 ng of genomic DNA, 5 pmol of forward and reverse primers, and 1 unit of AmpliTaq Gold DNA polymerase ¤Applied Biosystems, Foster City, CA¥. The amplification was performed with an initial determination at 95ôC for 10 min and 35 cycles of 20 s at 95ôC, 30 s at 55ôC, and 1 min at 72ôC, followed by a final extension step of 10 min at 72ôC. The forward and reverse primers used were: 5$-GCAGGCCAACATTCAAATTC-3$ and 5$-GGC-ATATCTGGGTGTCTAATGG-3$ for exon 1, 5$-CTTCTT-GGGGCAAAATTATCA-3$ and 5$-GTTTCATCCAAACA-TATCTTGCT-3$ for exon 4, and 5$-TGAAGAAATTCCC-CTTTATCG-3$ and 5$-CTGGCTTCTCAGGGTAAATGA-3$ for exon 8. To sequence the PCR products, either amplification primer was used for each exon. The primers for direct sequencing of the remaining exons were the same as described previously. 6¥ The sequencing reaction was performed using the ABI Prism BigDye Terminator v3.0 Ready Reaction Cycle Sequencing Kit ¤Applied Biosystems¥, followed by electrophoresis with the ABI PRISM 3730 DNA Analyzer ¤Applied Biosystems¥. Sequence data were analyzed using DNASIS Pro ¤Hitachi Software, Tokyo, Japan¥ and Sequencher ¤Gene Codes, Ann Arbor, MI¥.
Preparation of recombinant CYP2C76 proteins: For functional analysis of CYP2C76 variants, the construction of expression plasmids, protein expression in Eschelichia coli, and preparation of membrane fraction from bacteria cells were performed as described previously, 3¥ except that the pCW vector did not contain reductase cDNA. Sitedirected mutagenesis was performed using a QuickChange XL II kit ¤Stratagene, La Jolla, CA¥ according to the manufacturerös instructions with the primers listed in Table 1 . The entire coding sequence was verified by sequencing for each variant. Enzyme assays: Progesterone 16AE-hydroxylation was determined as described previously. 2¥ Briefly, the standard incubation mixtures contained recombinant CYP2C76 protein ¤0.04 nM¥ fortified with NADPH-P450 reductase 
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¤0.08 nM¥, an NADPH-generating system, and progesterone ¤10 or 100 µM¥ in 50 mM potassium phosphate buffer ¤pH 7.4¥. Incubation was carried out at 37ôC for 15 min and terminated by adding 1.5 ml of ethyl acetate/0.3 M NaCl. After centrifugation at 7,500 ' g for 10 min, metabolites in supernatant were analyzed by high-performance liquid chromatography with a UV detector. For kinetic analysis, progesterone 16AE-hydroxylation was measured using six concentrations of the substrate between 10 and 200 µM, and non-linear regression analysis was performed using GraphPad Prism ¤GraphPad, La Jolla, CA¥. Docking simulation: To establish a model of a threedimensional structure, the cynomolgus CYP2C76 amino acid sequence ¤wild type or A103T¥ was aligned with human CYP2C9 ¤Protein Data Bank code 1OG5¥ using the MOE software ¤version 2010.10; Chemical Computing Group, Montreal, Canada¥ according to the manufacturerös instructions. The energy of the CYP2C76 structure was minimized using the CHARM22 force field. Docking simulations were performed using the MMFF94x force field for progesterone with the homology model of CYP2C76. For each docking simulation, twenty solutions generated were ranked according to total interaction energy ¤U value¥.
Results and Discussion
Re-sequencing of CYP2C76 in 74 cynomolgus and 30 rhesus macaques identified a total of 18 non-synonymous variants. Among these variants, 7 were in substrate recognition sites ¤SRSs¥ important for protein function: c.307GhA and c.308ChT in SRS1, c.707AhT in SRS3, c.883AhG in SRS4, c.1088ChT, c.1091AhG, and c.1093GhT in SRS5 ¤Table 2¥. Of these 18 variants, 14 ¤78%¥ were shared by both lineages ¤Table 2¥. Similarly, the variants found in cynomolgus macaques were shared by rhesus macaques, 7¥ including P450 genes, 8¥ suggesting that generic variants can be used interchangeably in these macaque lineages. Moreover, 4 ¤22%¥ of 18 non-synonymous variants were unique to Indochinese cynomolgus macaques whereas all the variants found in Indonesian animals were shared by Indochinese animals ¤Table 2¥. A similar regional difference in allele frequency has also been found in rhesus macaques from China and India, 9¥ and in cynomolgus macaques from Indochina and Indonesia for CYP3A4 and CYP3A5.
8¥ Because non-synonymous variants unique to one population could result in variability of drug-metabolizing properties in different populations, it is prudent to use animals from the same population in drug metabolism studies.
To investigate the effect of each variant for drugmetabolizing enzyme activity, progesterone 16AE-hydroxylation was measured using 18 CYP2C76 variant proteins heterologously expressed in E. coli. At 10 µM of progesterone, 3 variants, L65F ¤c.193ChT¥, M310L ¤c.928AhT¥, and N364S ¤c.1091AhG¥, showed reduced metabolic activities ¤53, 56, and 61% of wild-type activity¥, respectively, while one variant, c.193ChT ¤L65F¥, showed reduced metabolic activity ¤52% of wild-type activity¥ at 100 µM progesterone ¤Fig. 1¥. Other variants did not show substantial differences in progesterone 16AE-hydroxylation at either concentration of substrate as compared with the wild type. According to a kinetic study of progesterone 16AE-hydroxylation, K m values of M310L and N364S variants were 2.4 and 3.2-fold higher Nucleotide changes were detected by a comparison with the CYP2C76 cDNA sequence ¤GenBank accession no. DQ074807¥.
Fig. 1. Progesterone 16¡-hydroxylase activity of CYP2C76 variants found in cynomolgus macaques
The cynomolgus CYP2C76 variant proteins expressed in E. coli was used to measure progesterone 16¡-hydroxylation using 10 or 100 µM of substrate as described in Materials and Methods. Values are based on duplicate determinations.
than wild-type protein, whereas the K m value of L65F was not substantially different from that of the wild-type protein ¤Table 3¥. V max values of M310L and N364S variants were not substantially different from that of the wild-type protein, whereas the V max value of L65F was substantially different from that of the wild-type protein ¤Table 3¥. The resulting V max /K m values of L65F, M310L, and N364S variants were 36, 41, and 44% of that of wild-type activity ¤Table 3¥. Therefore, the metabolic activity of progesterone hydroxylation might be lower in the animals with these variants than wild-type animals. Although other variants did not show metabolic activities different from the wild-type protein in progesterone metabolism, they might influence protein function with different substrates as has been evidenced in human P450s. For example, six CYP2C9 variants, CYP2C9*3 ¤I359L¥, *13 ¤L90P¥, *26 ¤T130R¥, *28 ¤Q214L¥, *30 ¤A477T¥, and *33 ¤R132Q¥, exhibit substrate-dependent changes in their kinetic parameters. 10¥ Moreover, the previous study indicated the importance of the residues proximal to residue 103 for reduced metabolic activity of CYP2C9.
11¥ Therefore, it is of great interest to investigate the effects of the CYP2C76 variants found in this study for their drug-metabolizing enzyme activities using other CYP2C76 substrates.
To investigate possible structural causes for the reduction in progesterone 16AE-hydroxylation, structural models of CYP2C76 and its variant ¤L65F¥ were established and subjected to docking simulation with progesterone. In the CYP2C76 model, the C16-atom of progesterone appeared to be far from the P450 heme in the L65F variant ¤Fig. 2¥. These results suggest that the reduced catalytic activity of the L65F variant in progesterone 16AE-hydroxylation is possibly due to a longer distance between progesterone and the P450 heme in the 3-dimensional active site of the CYP2C76 protein.
Since CYP2C76 is not orthologous to any human P450 and is partly responsible for the differences in drug metabolism from humans, CYP2C76 null animals could show more similar drug-metabolizing profiles to humans. To establish the CYP2C76 null animals, the CYP2C76 null allele ¤c.449TGhA¥ previously found in cynomolgus macaques can be utilized 6¥ ; however, the low allele frequency of this allele has hampered identification of the homozygotes. In this study, the comprehensive survey of a larger number of genomes did not find null alleles in cynomolgus or rhesus macaques. Due to the low frequency of null alleles in general, a much greater number of genomes might be needed to find null alleles. Alternatively, CYP2C76 null animals might not survive if CYP2C76 is essential for embryonic or fetal development, considering that CYP2C76 metabolizes progesterone, an essential hormone during development, as shown in this study. In the latter case, the animals heterozygous for the null allele can be assessed if they show more similar drug-metabolizing profiles to humans.
In addition to CYP2C76, other macaque P450 genes are also polymorphic in macaques, including CYP3A4 and CYP3A5.
8¥ Genetic variants in these P450 genes might possibly account for inter-animal variations in drug metabolism. It is of great importance to investigate macaque P450 variants to better understand potential inter-animal variations in drug metabolism.
In this study, progesterone 16AE-hydroxylation was measured to assess the effect of the identified variant for CYP2C76 protein function. In the human liver, progesterone is metabolized into various metabolites: 16AE-hydroxylated progesterone is approximately 10-fold less than 6Ç- The heme group of the P450 is shown at the lower part of each of the figures. In the figure, oxygen, nitrogen, and iron are colored with red, blue, and light blue, respectively. The distances between Featom in P450 heme and C16-atom of progesterone were calculated to be 6.08 and 10.47 Å in CYP2C76 and its L65F variant, respectively. A homology model of CYP2C76 was constructed as described in Materials and Methods. 2¥ Therefore, the substrates specific for CYP2C76 need to be found to further assess the effect of genetic variants for CYP2C76 function in vivo.
In conclusion, 18 non-synonymous variants were found in cynomolgus and rhesus macaques, and characterized. Among these, L65F, M310L, and N364S variants showed reduction of metabolic activity in progesterone 16AE-hydroxylation. These variants could be associated with lower metabolic activities of CYP2C76 in cynomolgus and rhesus macaques. The data presented in this study would be useful when conducting drug metabolism studies using cynomolgus and rhesus macaques.
